Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary

Adicet Bio announces acceptance of three abstracts for poster presentation at SITC Annual Meeting

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38^th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.

Details of the poster presentation are as follows:

Abstract Title: Assay Development and Quantitative Detection of ADI-001, a CD20-Targeted γδ1 CAR T Therapy, using AlloCell, a Universal Assay for Monitoring of “Off-the-Shelf" Allogeneic Cell Therapies
Poster/Abstract Number: 684
Presenting Authors: Jackie Wilde, MS & Monica Moreno, PhD
Date/Time: November 4, 2023, from 9:00 a.m. - 8:30 p.m. PDT

Abstract Title: ADI-925: An Allogeneic “Off-the-Shelf" Chimeric Adapter (CAd) γδ T Cell Therapy Targeting NKG2D Ligand-Expressing Cancers
Poster/Abstract Number: 265
Presenting Authors: Marissa Herrman, PhD
Date/Time: November 3, 2023, from 9:00 a.m. - 8:30 p.m. PDT

Abstract Title: Disruption of the Cytokine Signaling Checkpoint CIS Enhances Serial-Killing and Anti-Tumor Activity of CAR-Engineered γδ T Cells
Poster/Abstract Number: 246
Presenting Authors: Beibei Ding, PhD
Date/Time: November 4, 2023, from 9:00 a.m. - 8:30 p.m. PDT

These abstracts will be available as a supplement in the Journal for ImmunoTherapy of Cancer (JITC) on Tuesday, October 31, 2023 at 9:00 a.m. EDT on www.sitcancer.org.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230927031162/en/

Adicet Bio, Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.